首页> 美国卫生研究院文献>PLoS Clinical Trials >An Efficient Microarray-Based Genotyping Platform for the Identification of Drug-Resistance Mutations in Majority and Minority Subpopulations of HIV-1 Quasispecies
【2h】

An Efficient Microarray-Based Genotyping Platform for the Identification of Drug-Resistance Mutations in Majority and Minority Subpopulations of HIV-1 Quasispecies

机译:一个有效的基于微阵列的基因分型平台,用于鉴定HIV-1准种的多数和少数亚群中的抗药性突变。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

The response of human immunodeficiency virus type 1 (HIV-1) quasispecies to antiretroviral therapy is influenced by the ensemble of mutants that composes the evolving population. Low-abundance subpopulations within HIV-1 quasispecies may determine the viral response to the administered drug combinations. However, routine sequencing assays available to clinical laboratories do not recognize HIV-1 minority variants representing less than 25% of the population. Although several alternative and more sensitive genotyping techniques have been developed, including next-generation sequencing (NGS) methods, they are usually very time consuming, expensive and require highly trained personnel, thus becoming unrealistic approaches in daily clinical practice. Here we describe the development and testing of a HIV-1 genotyping DNA microarray that detects and quantifies, in majority and minority viral subpopulations, relevant mutations and amino acid insertions in 42 codons of the pol gene associated with drug- and multidrug-resistance to protease (PR) and reverse transcriptase (RT) inhibitors. A customized bioinformatics protocol has been implemented to analyze the microarray hybridization data by including a new normalization procedure and a stepwise filtering algorithm, which resulted in the highly accurate (96.33%) detection of positive/negative signals. This microarray has been tested with 57 subtype B HIV-1 clinical samples extracted from multi-treated patients, showing an overall identification of 95.53% and 89.24% of the queried PR and RT codons, respectively, and enough sensitivity to detect minority subpopulations representing as low as 5–10% of the total quasispecies. The developed genotyping platform represents an efficient diagnostic and prognostic tool useful to personalize antiviral treatments in clinical practice.
机译:人类免疫缺陷病毒1型(HIV-1)准种对抗逆转录病毒疗法的反应受构成不断发展的种群的突变体的整体影响。 HIV-1准种内的低丰度亚群可能决定了对所用药物组合的病毒反应。但是,临床实验室可用的常规测序测定法不能识别代表不到25%人口的HIV-1少数民族变异。尽管已经开发出了多种替代方法和更敏感的基因分型技术,包括下一代测序(NGS)方法,但它们通常非常耗时,昂贵且需要训练有素的人员,因此在日常临床实践中成为不切实际的方法。在这里,我们描述了HIV-1基因分型DNA芯片的开发和测试,该芯片检测并量化了大多数和少数病毒亚群,与细菌具有耐药性和多重耐药性相关的pol基因的42个密码子中的相关突变和氨基酸插入(PR)和逆转录酶(RT)抑制剂。通过包括新的标准化程序和逐步过滤算法,已实现了定制的生物信息学协议来分析微阵列杂交数据,从而可对阳性/阴性信号进行高精度(96.33%)的检测。该芯片已用从多名治疗患者中提取的57个B亚型HIV-1临床样品进行了测试,分别显示了所查询的PR和RT密码子的总鉴定率分别为95.53%和89.24%,并且具有足够的灵敏度来检测代表低至准种总数的5-10%。开发的基因分型平台代表了一种有效的诊断和预后工具,可用于在临床实践中个性化抗病毒治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号